Drug Package Insert Regulations

Dave Hoffman

Dave Hoffman is the Murray Shusterman Professor of Transactional and Business Law at Temple Law School. He specializes in law and psychology, contracts, and quantitative analysis of civil procedure. He currently teaches contracts, civil procedure, corporations, and law and economics.

You may also like...

1 Response

  1. Ken Arromdee says:

    Drug companies want to reduce their liability costs (which may mean giving warnings), but they also want to make the drug look good (which may mean omitting warnings). These are conflicting goals. One way to reconcile these goals is to give warnings but to do so in the least prominent way possible. Entirely leaving warnings out of some types of communication may serve this goal as long as the consumer can be expected to receive the warning somehow.